Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 13/20 | 0.56 |
| ▸ | F2 | P00734 | 11/20 | 0.56 |
| ▸ | F7 | P08709 | 9/20 | 0.46 |
| ▸ | F10 | P00742 | 6/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.46 |
| ▸ | F12 | P00748 | 3/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439271 | 1.00 | F11 (0.56) | F11F2F7F10PRSS1 | |
| SCHEMBL6435693 | 0.98 | F11 (0.59) | F11F2F7F10PRSS1 | |
| SCHEMBL6435689 | 0.98 | F11 (0.59) | F11F2F7F10PRSS1 | |
| SCHEMBL6438353 | 0.95 | F11 (0.53) | F11F2F7F10PRSS1 | |
| SCHEMBL6438358 | 0.95 | F11 (0.53) | F11F2F7F10PRSS1 | |
| SCHEMBL6438377 | 0.92 | F2 (0.52) | F11F2F7F10F3 | |
| SCHEMBL6438374 | 0.92 | F2 (0.52) | F11F2F7F10F3 | |
| SCHEMBL6438817 | 0.91 | F11 (0.62) | F11F2F7F10PRSS1 | |
| SCHEMBL6439323 | 0.91 | F11 (0.62) | F11F2F7F10PRSS1 | |
| SCHEMBL6438813 | 0.91 | F11 (0.62) | F11F2F7F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |